Hemab

Copenhagen, Denmark

Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.

$157.0M raised

Oct 2025

Series C

Top Investors

RA Capital ManagementSofinnova PartnersNovo HoldingsInvusRock Springs Capital

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Hemab raised?

Hemab has raised $157.0M in total funding. The most recent round was Series C. The last funding was announced in October 2025.

Who are Hemab's investors?

Hemab's investors include RA Capital Management, Sofinnova Partners, Novo Holdings, Invus, Rock Springs Capital.

Where is Hemab headquartered?

Hemab is headquartered in Copenhagen, Denmark.

What does Hemab do?

Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.

What stage is Hemab at?

Hemab is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 27, 2025.

MLA

"Hemab — Funding & Investors." VCBacked, October 27, 2025, https://www.vcbacked.co/company/hemab. Accessed June 4, 2026.

APA

VCBacked. (2025). Hemab — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/hemab

Wikipedia (cite web)

{{cite web |title=Hemab — Funding & Investors |url=https://www.vcbacked.co/company/hemab |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 27, 2025.